SABCS 2022: Updated survival results of the randomized, phase 3 study DESTINY-Breast03 + Q & A

Поделиться
HTML-код
  • Опубликовано: 16 окт 2024
  • Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated survival results of the randomized, phase 3 study DESTINY-Breast03
    Recorded @ SABCS 2022, December 7/More about SABCS Reports @ oncoletter.ch

Комментарии •